Akèy › Maladi Crohn › Texas › Houston
Etid klinik pou Maladi Crohn nan Houston, TX
17 etid pou Maladi Crohn ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Ap rekriteFaz 3
- Baylor College of Medicine Medical Center ( Site 5020), Houston
- Michael E. DeBakey VA Medical Center ( Site 5086), Houston
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Ap rekriteFaz 2
- Integrity Advanced Therapeutics /ID# 283871, Houston
- Novel Research - Bellaire /ID# 280925, Bellaire · 7 mi lwen
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ap rekriteFaz 4
- Kelsey Research Foundation, Houston
- MedCare Pharma LLC, Houston
- Spring Clinical Research, Houston
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Ap rekriteFaz 2
- Houston Methodist Hospital /ID# 265533, Houston
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2/3
- Victorium Clinical Research, Houston
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2
- Novel Research, LLC, Bellaire · 7 mi lwen
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2
- The University of Texas Health Science Center at Houston, Houston
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Ap rekriteFaz 4
- The University of Texas Health Science Center at Houston, Houston
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
Ap rekriteEtid obsèvasyon
- BAMC, Houston
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Ap rekrite
- Baylor College of Medicine, Houston
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Ap rekriteFaz 3
- Texas Children's Hospital - Baylor - PIN, Houston
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Ap rekriteFaz 3
- Texas Children's Hospital, Houston
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Ap rekriteFaz 2
- Houston Methodist Hospital, Houston
- Novel Research, LLC, Bellaire · 7 mi lwen
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
Ap rekriteFaz 2
- Mirador Therapeutics Selected Site, Houston
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Ap rekriteFaz 4
- Houston Methodist Hospital, Houston
Etid Maladi Crohn nan lòt vil
- New York City, NY35 etid
- Cleveland, OH19 etid
- St. Louis, MO19 etid
- Boston, MA19 etid
- Miami, FL19 etid
- Orlando, FL17 etid
- Atlanta, GA17 etid
- Tyler, TX16 etid
- San Diego, CA15 etid
- San Antonio, TX15 etid
- Los Angeles, CA15 etid
- Philadelphia, PA13 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.